Chiron in £542m takeover bid for Powderject

POWDERJECT, the company that made history last week as the first UK biotech group to offer a dividend, yesterday recommended that shareholders turn down their payouts in favour of a £542 million takeover by US drug-maker Chiron.

PowderJect takeover gathers pace as profits soar 23,400 per cent

VACCINE maker PowderJect Pharmaceuticals today revealed that talks over a possible bid for the firm had reached an advanced stage as it posted a colossal 23,400 per cent jump in annual profits.

More top stories

Mystery bidder eyes Powderject

DRUGS supplier Powderject revealed it has received a fresh takeover approach from an undisclosed bidder, but declined to give further details.

Powderject reopens talks with Chiron

POWDERJECT Pharmaceuticals, the vaccines company run by Labour party doner Paul Drayson, is understood to have resurrected takeover talks with US firm Chiron Corporation.

'No link' in vaccine deal

THE UK’s National Audit Office has found "no link" between drug firm PowderJect winning a £32 million smallpox vaccine contract and donations by the head of the company to the Labour Party.

PowderJect in line for £50m contract

VACCINE company PowderJect, headed by Labour donor Paul Drayson, is set to win a second multi-million pound contract from the government after rival Acambis withdrew from the bidding.

Drayson quits PowderJect chairmanship

POWDERJECT Pharmaceuticals’ Paul Drayson is to step down as chairman of the vaccines group and hand over the role to vice-chairman Gerald Moller. Drayson will remain as chief executive of the group.

Powderject eyes mergers

POWDERJECT Pharmaceuticals remains committed to growth through mergers or acquisitions, despite the recent collapse of talks about a takeover of the firm, the British vaccines maker’s chief executive has said.

Flu vaccine boosts PowderJect

VACCINE maker PowderJect posted strong first-half profits and revealed progress in its new HIV vaccine, but the City questioned whether the upturn fuelled the company’s case for an improved takeover bid.

ASDA to buy new doses of PowderJect's flu vaccines

ASDA, the UK supermarket chain, is to buy more flu jabs from PowderJect, the UK biotechnology company, after the success of its in-store vaccination sales day two weeks ago.

Claims GSK set to enter bidding for PowderJect

GLAXOSMITHKLINE has emerged as a second possible bidder for PowderJect Pharmaceuticals, according to a report today which cites PowderJect’s bankers.

PowderJect soars 65%

VACCINE-MAKER PowderJect is thought to be looking for a bid of about £6-7 a share - valuing the company at £540-640 million - after it confirmed that it has received a number of takeover approaches.

Powderject reveals takeover advances

POWDERJECT Pharmaceuticals today confirmed it has received approaches from a number of interested parties, but insiders hinted the board would reject the bids, leading to the possibility of a takeover tussle.

Flu vaccine a tonic for firm

POWDERJECT Pharmaceuticals has forecast a 30 per cent rise in sales this year of its top-selling flu vaccine and dispelled fears of a glut in the key US market.

Expanding PowderJect sets up sales force of 25

POWDERJECT, the company mired in a cash-for-contract controversy, is to set up a 25-strong sales force, underlining its transformation from start-up to profitable business.

Profit warning wipes £91m off PowderJect

MORE than £91 million - nearly one-quarter - was slashed from the stock market value of PowderJect Pharmaceuticals yesterday after the biotech company put out a profit warning.

PowderJect sees shares plummet 18.5% after drug recall

BRITISH drug maker PowderJect Pharmaceuticals today saw its shares slump 18.5 per cent after warning of a drop in full-year profits.

Vaccine recall hits shares at drug firm

BRITISH drug maker PowderJect Pharmaceuticals today saw its shares slump 18.5 per cent after warning of a drop in full-year profits.

PowderJect goes into the black

PAUL Drayson, chairman and chief executive of PowderJect, said he plans to make further donations to the Labour Party, as the company revealed the huge benefits it expects from a new government contract.

Donors who have benefited

PAUL DRAYSON, the chief executive of PowderJect Pharmaceuticals, wrote Labour two cheques for £50,000 - the second of which came to light only last week. It put a new perspective on the £32 million smallpox vaccine contract his company won from the Department of Health in April.

Page 1 of 1

Back to the top of the page